The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications

Calcific aortic valve stenosis (CAS), the most prevalent valvular disease worldwide, has been demonstrated to frequently occur in conjunction with coronary artery disease (CAD), the third leading cause of death worldwide. Atherosclerosis has been proven to be the main mechanism involved in CAS and C...

Full description

Saved in:
Bibliographic Details
Published in:Progress in cardiovascular diseases 2023-07, Vol.79, p.89-99
Main Authors: Abdul-Rahman, Toufik, Lizano-Jubert, Ileana, Garg, Neil, Talukder, Suprateeka, Lopez, Pablo Perez, Awuah, Wireko Andrew, Shah, Rohan, Chambergo, Diego, Cantu-Herrera, Emiliano, Farooqi, Mobeen, Pyrpyris, Nikolaos, de Andrade, Heloisa, Mares, Adriana C., Gupta, Rahul, Aldosoky, Wesam, Mir, Tanveer, Lavie, Carl J., Abohashem, Shady
Format: Article
Language:English
Subjects:
Atherosclerosis
Calcific aortic stenosis
Coronary artery disease
Inflammation
Pathophysiology
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Calcific aortic valve stenosis (CAS), the most prevalent valvular disease worldwide, has been demonstrated to frequently occur in conjunction with coronary artery disease (CAD), the third leading cause of death worldwide. Atherosclerosis has been proven to be the main mechanism involved in CAS and CAD. Evidence also exists that obesity, diabetes, and metabolic syndrome (among others), along with specific genes involved in lipid metabolism, are important risk factors for CAS and CAD, leading to common pathological processes of atherosclerosis in both diseases. Therefore, it has been suggested that CAS could also be used as a marker of CAD. An understanding of the commonalities between the two conditions may improve therapeutic strategies for treating both CAD and CAS. This review explores the common pathogenesis and disparities between CAS and CAD, alongside their etiology. It also discusses clinical implications and provides evidence-based recommendations for the clinical management of both diseases. Central illustration outlining shared risk factors and pathobiology between CAS and CAD, in addition to recommended management. [Display omitted] •Atherosclerosis has been proven to be the main mechanism involved in CAS and CAD.•Statins have been supposed to reduce the progression of AS; however, results of several studies have failed to show any benefit.•The application of TAVR in the management of significant concomitant CAD still needs to be clarified.
ISSN:0033-0620
1532-8643
DOI:10.1016/j.pcad.2023.06.002